Morgan Stanley’s aTyr Pharma ATYR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $802K | Buy |
1,343,636
+118,169
| +10% | +$77.2K | ﹤0.01% | 5324 |
|
|
2026
Q1 | $956K | Sell |
1,225,467
-177,542
| -13% | -$150K | ﹤0.01% | 5163 |
|
|
2025
Q4 | $1.1M | Buy |
1,403,009
+692,668
| +98% | +$568K | ﹤0.01% | 5139 |
|
|
2025
Q3 | $512K | Buy |
710,341
+450,375
| +173% | +$2.04M | ﹤0.01% | 5489 |
|
|
2025
Q2 | $1.32M | Sell |
259,966
-2,713
| -1% | -$10.7K | ﹤0.01% | 4965 |
|
|
2025
Q1 | $793K | Buy |
262,679
+221,466
| +537% | +$808K | ﹤0.01% | 5114 |
|
|
2024
Q4 | $149K | Buy |
41,213
+41,212
| +4,121,200% | +$125K | ﹤0.01% | 5890 |
|
|
2024
Q3 | $2 | Hold |
1
| – | – | ﹤0.01% | 7915 |
|
|
2024
Q2 | $2 | Sell |
1
-19,717
| -100% | -$34.3K | ﹤0.01% | 7834 |
|
|
2024
Q1 | $38.5K | Buy |
19,718
+3,795
| +24% | +$6.62K | ﹤0.01% | 6311 |
|
|
2023
Q4 | $22.5K | Buy |
15,923
+13,519
| +562% | +$17.3K | ﹤0.01% | 6421 |
|
|
2023
Q3 | $3.8K | Sell |
2,404
-51
| -2% | -$94 | ﹤0.01% | 6978 |
|
|
2023
Q2 | $5.3K | Buy |
2,455
+171
| +7% | +$373 | ﹤0.01% | 6974 |
|
|
2023
Q1 | $4.8K | Buy |
+2,284
| New | +$5K | ﹤0.01% | 7059 |
|
|
2022
Q2 | – | Sell |
-72
| Closed | – | – | 8014 |
|
|
2022
Q1 | $0 | Sell |
72
-20,393
| -100% | -$116K | ﹤0.01% | 8148 |
|
|
2021
Q4 | $153K | Buy |
+20,465
| New | +$171K | ﹤0.01% | 6205 |
|
|
2020
Q4 | – | Sell |
-1,311
| Closed | -$4K | – | 7130 |
|
|
2020
Q3 | $4K | Sell |
1,311
-2,433
| -65% | -$9.99K | ﹤0.01% | 6486 |
|
|
2020
Q2 | $17K | Buy |
+3,744
| New | +$13.6K | ﹤0.01% | 6047 |
|
|
2019
Q2 | – | Sell |
-244
| Closed | -$2K | – | 6765 |
|
|
2019
Q1 | $2K | Sell |
244
-33
| -12% | -$235 | ﹤0.01% | 6476 |
|
|
2018
Q4 | $2K | Hold |
277
| – | – | ﹤0.01% | 6444 |
|
|
2018
Q3 | $3K | Sell |
277
-1,009
| -78% | -$11K | ﹤0.01% | 6527 |
|
|
2018
Q2 | $16K | Sell |
1,286
-7
| -0.5% | -$166 | ﹤0.01% | 6204 |
|
|
2018
Q1 | $48K | Sell |
1,293
-625
| -33% | -$29.3K | ﹤0.01% | 5894 |
|
|
2017
Q4 | $94K | Sell |
1,918
-198
| -9% | -$12.2K | ﹤0.01% | 5653 |
|
|
2017
Q3 | $150K | Sell |
2,116
-12
| -0.6% | -$556 | ﹤0.01% | 5462 |
|
|
2017
Q2 | $102K | Buy |
2,128
+320
| +18% | +$15K | ﹤0.01% | 5629 |
|
|
2017
Q1 | $89K | Buy |
1,808
+1,002
| +124% | +$45.8K | ﹤0.01% | 5643 |
|
|
2016
Q4 | $24K | Buy |
806
+615
| +322% | +$25.2K | ﹤0.01% | 5956 |
|
|
2016
Q3 | $8K | Sell |
191
-155
| -45% | -$6.7K | ﹤0.01% | 6156 |
|
|
2016
Q2 | $14K | Buy |
346
+147
| +74% | +$6.83K | ﹤0.01% | 5966 |
|
|
2016
Q1 | $11K | Sell |
199
-138
| -41% | -$10.5K | ﹤0.01% | 6113 |
|
|
2015
Q4 | $47K | Buy |
337
+187
| +125% | +$26.6K | ﹤0.01% | 5741 |
|
|
2015
Q3 | $21K | Sell |
150
-5
| -3% | -$1.14K | ﹤0.01% | 6039 |
|
|
2015
Q2 | $40K | Buy |
+155
| New | +$48.1K | ﹤0.01% | 5935 |
|
Other funds holding ATYR
GCP
KCM
Morgan Stanley's ATYR Position: Q2 2026 in Review
Morgan Stanley increased its aTyr Pharma (ATYR) stake by 9.6% in Q2 2026, buying an estimated $77.2K and bringing the position to 1,343,636 shares worth $802K. The position accounts for ﹤0.01% of the portfolio, ranked #5324.
Morgan Stanley first reported a position in ATYR in Q2 2015 and has held it in 34 quarters since. The position peaked at $1.32M in Q2 2025. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.
- Morgan Stanley held 1,343,636 shares of aTyr Pharma worth $802K as of Q2 2026.
- Morgan Stanley bought 118,169 aTyr Pharma shares in Q2 2026, an estimated $77.2K.
- aTyr Pharma made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5324 holding.
- Morgan Stanley first reported a position in aTyr Pharma in Q2 2015 and has held it in 34 quarters since.
- Morgan Stanley's aTyr Pharma position peaked at $1.32M in Q2 2025.
- 90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.